Clinical data | |
---|---|
Trade names | Aimax, Suisynchron, Turisynchron |
Other names | Methallibure; Methallibur; ICI-33828; AY-61122; NSC-69536 |
Drug class | Antigonadotropin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.011.952 |
Chemical and physical data | |
Formula | C7H14N4S2 |
Molar mass | 218.34 g·mol−1 |
3D model ( JSmol) | |
| |
|
Metallibure ( INN ) (brand names Aimax, Suisynchron, Turisynchron; former developmental code names ICI-33828, AY-61122, NSC-69536), also known as methallibure ( USAN , BAN ) or methallibur ( German), is a medication which was introduced in 1973 and has been used in veterinary medicine to synchronize estrus. [1] [2] It was withdrawn in the United States and Europe due to teratogenicity and has been replaced with altrenogest (Regumate, Matrix), a progestin. [2] [3]
The precise mechanism of action of metallibure is unknown. [2] It has been described as a " nonsteroidal antigonadotropin" and it appears to act directly on the pituitary gland and/or hypothalamus to suppress gonadotropin secretion. [2] However, metallibure has also been reported to be an antiprogestogen and to act specifically via inhibition of the biosynthesis or secretion of progesterone. [4]
Metallibure has similar endocrinological effects in women. [5] It is associated with several unpleasant side effects including appetite loss, nausea, occasional vomiting, lethargy, and drowsiness. [5] Animal toxicity studies revealed that the medication induced the development of cataracts, and this resulted in the termination of its clinical development. [5]
Clinical data | |
---|---|
Trade names | Aimax, Suisynchron, Turisynchron |
Other names | Methallibure; Methallibur; ICI-33828; AY-61122; NSC-69536 |
Drug class | Antigonadotropin |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.011.952 |
Chemical and physical data | |
Formula | C7H14N4S2 |
Molar mass | 218.34 g·mol−1 |
3D model ( JSmol) | |
| |
|
Metallibure ( INN ) (brand names Aimax, Suisynchron, Turisynchron; former developmental code names ICI-33828, AY-61122, NSC-69536), also known as methallibure ( USAN , BAN ) or methallibur ( German), is a medication which was introduced in 1973 and has been used in veterinary medicine to synchronize estrus. [1] [2] It was withdrawn in the United States and Europe due to teratogenicity and has been replaced with altrenogest (Regumate, Matrix), a progestin. [2] [3]
The precise mechanism of action of metallibure is unknown. [2] It has been described as a " nonsteroidal antigonadotropin" and it appears to act directly on the pituitary gland and/or hypothalamus to suppress gonadotropin secretion. [2] However, metallibure has also been reported to be an antiprogestogen and to act specifically via inhibition of the biosynthesis or secretion of progesterone. [4]
Metallibure has similar endocrinological effects in women. [5] It is associated with several unpleasant side effects including appetite loss, nausea, occasional vomiting, lethargy, and drowsiness. [5] Animal toxicity studies revealed that the medication induced the development of cataracts, and this resulted in the termination of its clinical development. [5]